-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Tango Therapeutics, Raises Price Target to $19

Benzinga·03/06/2026 13:45:41
Listen to the news
Wedbush analyst Robert Driscoll maintains Tango Therapeutics (NASDAQ:TNGX) with a Outperform and raises the price target from $15 to $19.